# GKL-006Allo Injection in Patients With Advanced Solid Tumors

> **NCT07704515** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Beijing Gene Key Life Technology Co., Ltd** · enrollment: 27 (estimated)

## Conditions studied

- Solid Tumor Malignancies

## Interventions

- **BIOLOGICAL:** GKL-006Allo Injection

## Key facts

- **NCT ID:** NCT07704515
- **Lead sponsor:** Beijing Gene Key Life Technology Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-30
- **Primary completion:** 2028-09-30
- **Final completion:** 2029-01-31
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2026-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07704515

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07704515, "GKL-006Allo Injection in Patients With Advanced Solid Tumors". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07704515. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*